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Selection of patients for randomised clinical trials may have a large impact on the applicability of the study results to the
general population presenting the same disorder. However, clinical characteristics and outcome data on non-entered
patients are usually not available. The effects of patient selection for the EORTC 10853 trial investigating the role of
radiotherapy in breast conserving therapy for ductal carcinoma in situ have been studied, in an analysis of all patients treated
for ductal carcinoma in situ in ﬁve participating institutes. The reasons for not entering patients were evaluated and
treatment results of the randomised patients were compared to those not entered. A total of 910 patients were treated for
ductal carcinoma in situ. Of these, 477 (52%) were ineligible, with the size of the lesion being the main reason for
ineligibility (30% of all ductal carcinoma in situ). Of the 433 eligible patients, 278 (64%) were randomised into the trial. The
main reasons for non-entry of eligible patients were either physicians’ preference for one of the treatment arms (26%) or
patients’ refusal (9%). These percentages showed signiﬁcant variation among the institutes. At 4 years follow-up, those
patients not entered in the trial and treated with local excision and radiotherapy, had higher local recurrence rates than the
patients randomised in the trial and treated with the same approach, (17 vs 2%, P=0.03). The patients treated with local
excision alone had equal local recurrence rates (11% in both groups). Selection of patients may explain the differences in
outcome of the randomised patients, and those not-entered. Thus, the results of this trial may not be applicable to all
patients with ductal carcinoma in situ.
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Results of randomised clinical trials usually form the main source
for deﬁning evidence based treatment. Because it is necessary to
deﬁne clearly the criteria for eligibility, patient selection may
produce a trial population which differs substantially from the
general population with the disease to whom the results of the trial
are intended to be applied. Not only trial eligibility criteria may
determine the study population, but also factors such as patient’s
and doctor’s preferences may have an impact. For these reasons,
a comparison of patients entered in a trial with all the non-entered
cases with the disease for which the trial was designed may give
insight in the selection process and therefore in the interpretation
and general applicability of the trial results (Anonymous, 1994).
This information is hardly ever available, as trials usually do not
include registration and follow-up of non-entered patients with
the disease.
Between 1986 to 1996, the European Organization for Research
and Treatment of Cancer (EORTC) accrued patients in a phase III
randomised clinical trial (RCT) to investigate the role of radiother-
apy in breast conserving treatment (BCT) of ductal carcinoma in
situ (DCIS) of the breast. The ﬁrst results, indicating that radio-
therapy reduced the rate of both non-invasive and invasive local
recurrence, have been published recently (Julien et al, 2000).
There were large differences between the participating institutes
in the number of randomised patients: some centres entered over
100 patients in 6 years of participation, whereas others included
only a few patients during the whole 10 year period of the trial.
These differences could not be explained by the eligibility criteria
of the trial. This raised the question as to whether there were
differences in the rate of patients diagnosed with DCIS, and
whether additional criteria were used to select patients for the trial.
This might inﬂuence the applicability of the trial results to all
patients with DCIS.
The criteria for selection were studied in ﬁve participating insti-
tutes: Centre Henri Becquerel in Rouen, Policlinico di Careggi in
Florence, Guy’s Hospital in London, Institut Bergonie ￿ in Bordeaux
and The Netherlands Cancer Institute in Amsterdam. The objec-
tives of this study were to analyse entry rates and the reasons for
non-entry in these centres, to compare treatment results of entered
and non-entered patients, and to study possible effects on the
applicability of the trial results.
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A detailed description of the EORTC DCIS trial (protocol 10853)
has been given previously (Julien et al, 2000). In summary, patients
with clinically or mammographically detected DCIS with a maxi-
mum diameter of 5 cm were, following histologically conﬁrmed
complete local excision of the lesion, randomised between either
no further treatment or radiotherapy, 50 Gray in 25 fractions to
the whole breast. Exclusion criteria were age over 70 years, a prior
or concomitant malignancy other than basal cell carcinoma of the
skin or cone biopsied carcinoma in situ of the cervix, WHO perfor-
mance status 52 or mental conditions or social circumstances
precluding long-term follow-up, and patients with Paget’s disease
of the nipple.
Between 1986 and 1996 1010 patients were randomised by 46
institutes from 13 different countries.
The medical records were reviewed of all patients who were trea-
ted for DCIS of the breast in ﬁve institutes during the period of
trial participation. These institutes were responsible for the entry
of 27% of all patients in the trial. The ﬁve centres were selected
because they each have a complete prospective cancer registration
system, enabling the identiﬁcation of all patients treated for DCIS.
The number of DCIS cases treated per year in each institute during
the period of trial participation was divided by the total number of
operable breast cancer cases, to calculate the incidence of DCIS.
Entry rates were calculated by dividing the number of randomised
patients by the total number of patients treated for DCIS in each
institute. Reasons for non-entry, as well as data on method of
detection, treatment, follow-up and outcome were obtained by
review of the medical records.
Apart from reasons for ineligibility, also doctor’s and patient’s
preferences for trial participation or a particular treatment were
searched for. In eligible, but not entered patients, comments on
the reason for non-entry were searched in the medical ﬁle. Apart
from patient’s refusal, which was always well documented, it could
be stated that: ‘this type of DCIS requires additional radiotherapy’,
or ‘this subtype is very indolent, and therefore radiotherapy seems
to be overtreatment’, in which case this was considered indicative
for the reason for non-entry.
Reasons for non-entry were compared between the ﬁve institutes
by cross tabulation and P-values were calculated by the w
2 test.
Local recurrence-free intervals were deﬁned as the time between
the date of randomisation (for the randomised patients) or the
date of primary treatment (for the non-entered patients) and the
date of recurrence of disease in the ipsilateral breast. Local recur-
rence-free interval rates were calculated using the Kaplan Meier
technique (Kaplan and Meier, 1958), and compared using a 2-sided
log-rank test. The institutes are randomly referred to as A, B, C, D
and E.
RESULTS
The average number of patients with operable breast cancer treated
per year in the period of participation to the trial varied from 150
to 600 between the ﬁve institutes. The incidence of DCIS varied
from 5% in institute B and C, to 7% (A and E) to 10% (institute
D). In the study period 910 patients with DCIS were treated in the
ﬁve centres. Of these, 477 (52%) were not entered based on elig-
ibility criteria. The rate of ineligible patients varied between the
institutes from 44 to 66% (Table 1). Of the 433 eligible patients
278 (64%) were actually randomised, with large differences
between the institutes, varying from 41 to 100%. Ultimately, 278
of 910 patients (31%) entered the trial; the entry rates (number
of randomised vs total number of patients with DCIS) varied from
14 to 50%.
Table 2a shows the reasons for non-entry based on eligibility
criteria. Four hundred and seventy-seven patients were ineligible
with a total of 548 reasons stated; more than one reason for inelig-
ibility could be present. The main reason for ineligibility was the
size of the DCIS and/or margin involvement with 30% of all DCIS
being considered too extensive for BCT, and 3% having involved
margins. The percentage of patients with extensive DCIS or
involved margins varied from 21 to 47% between the institutes
(Table 2a).
One hundred and ﬁfty-ﬁve of 433 eligible patients (36%) did
not enter the trial because of doctors’ or patients’ preferences
(Table 2b). In 26% of the eligible patients the doctor’s preference
for a particular treatment was the reason for non-entry (range 0–
36%). Only in institute B no additional criteria for entry were
applied: in the other institutes physicians often based a choice of
therapy on the histologic differentiation type of DCIS. Forty-one
(9%) of all eligible patients did not enter the trial because they
refused to participate (range 0–36%, Table 2b).
Of all the 910 patients with DCIS 60% were treated with BCT
(range 46–74% between the institutes). Fifty-one per cent of all
the patients treated with BCT were entered in the trial. The treat-
ment of the non-entered patients consisted of mastectomy in 57%,
and BCT in 43% (Table 3). As expected, most patients with DCIS
that was considered too extensive were treated with mastectomy
(95%). The proportion of patients who were treated conservatively
outside the trial is similar in four institutes (30–36%), whereas in
institute D 60% of the non-entered patients were treated with BCT.
Here, many patients with an incomplete excision underwent radio-
therapy instead of a re-excision or mastectomy (19 of 25 patients
with involved margins treated with LE+RT). Eligible non-entered
patients were generally treated with BCT (79%) without RT
(60%). A notable exception again is institute D with only 64%
treated conservatively, and 37% without RT (P50.0001; Exact w
2
test in 364 table). In institute D mastectomy was the treatment
of choice for ‘comedo-type’ DCIS (20 patients with ‘comedo-type’
DCIS were treated with mastectomy; nine with LE+RT). In insti-
tutes A and C, and to a lesser extent in institutes D and E,
physicians preferred to treat well-differentiated DCIS cases outside
the trial without radiotherapy (52 of 54 non-entered eligible
patients were treated with LE only). In institute B, BCT usually
consisted of LE+RT. Thirty-six of the 41 patients who refused to
participate in the trial were treated with BCT.
Five hundred and sixty-ﬁve (63%) of the lesions were asympto-
matic, detected by mammographic screening. The rate of
mammographically detected DCIS varied from 47 to 77% between
the institutes (58% in A, 75% in B, 56% in C, 77% in D and 47%
in E). Twenty ﬁve per cent of the mammographically detected
lesions were too large for BCT, compared with 40% of the clini-
cally detected lesions (P50.001). Consequently, patients who
were eligible for the trial had a higher rate of mammographically
detected lesions than the patients who were ineligible (74 vs
53%, P50.001).
The median duration of follow-up for the trial patients was 51
months, for the non-entered patients 39 months. Follow-up was
complete for 96% of the patients. The 4-year local recurrence-free
interval rates are given in Table 4 for the randomised patients, for
the eligible non-entered, and ineligible cases. Five patients (1.4%)
had a chest wall recurrence following mastectomy (n=362). At 4
years, the eligible non-entered patients treated with local excision
alone had a 93% local recurrence-free interval, compared with
89% for the patients randomised to receive LE (s.e.=5.5, P=0.45).
Four of the 29 eligible non-entered patients treated with LE+RT
developed a local recurrence (4-year local recurrence-free interval
74%), compared to 12 of 133 of the LE+RT group in the trial
(4-year local recurrence-free interval 98%) (s.e.=13.4, P=0.075)
(Table 4). The majority of the recurrences in the LE+RT group
in the trial occurred after 4 years.
When all non-entered patients – eligible and ineligible – are
grouped together, those non-entered patients treated with LE+RT
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Table 1 Entry rates in ﬁve institutes
Institute
A B C D E Total P-value
Period of participation 1986–96 1992–95 1986–96 1990–95 1986–96 1986–96
Total patients with DCIS 224 40 252 292 102 910
Ineligible 148 (66%) 20 (50%) 123 (49%) 128 (44%) 58 (57%) 477 (52%) 50.001
Eligible 76 (34%) 20 (50%) 129 (51%) 164 (56%) 44 (43%) 433 (48%) 50.001
Entered 31 (14%) 20 (50%) 98 (39%) 100 (34%) 29 (28%) 278 (31%) 50.001
Per cent entered of eligible 41% 100% 76% 61% 66% 64% 50.001
Table 2a Ineligible patients in ﬁve institutes (per cent of all patients)
Institute
ABCDE
Eligibility criterion n (%) n (%) n (%) n (%) n (%) n (%) P value
DCIS too large for BCT 102 (46) 11 (28) 87 (35) 36 (12) 40 (39) 279 (30) 50.001
Margins not free 3 (1) 0 (0) 1 (0.4) 25 (9) 0 (0) 29 (3) 50.001
Paget’s disease 14 (6) 0 (0) 2 (0.8) 8 (3) 6 (6) 30 (3) 0.005
Age 4 70 years 18 (8) 4 (10) 26 (10) 14 (5) 12 (12) 74 (7) 0.093
Contralateral breast cancer 40 (18) 5 (13) 19 (8) 44 (15) 0 (0) 108 (12) 50.001
Previous other malignancy 12 (5) 1 (3) 4 (2) 7 (2) 1 (1) 25 (3) 0.081
Perf. status 5 2/mental condition 0 (0) 0 (0) 2 (0.8) 2 (0.7) 2 (2) 6 (0.6) 0.35
n=number of patients
Table 2b Non-entry of patients in ﬁve institutes due to additional factors (per cent of eligible patients)
Institute
Additional factors A B C D E Total
for non-entry n (%) n (%) n (%) n (%) n (%) n (%) P-value
Doctor’ preference
Well differentiated 13 (7) 0 (0) 19 (15) 18 (11) 4 (9) 54 (12) 0.22
Poorly differentiated 2 (3) 0 (0) 2 (1.6) 29 (18) 3 (7) 36 (8) 50.001
Other doctor’s reason 1 (1.3) 0 (0) 1 (0.8) 3 (2) 0 (0) 5 (1) 0.82
Not considered for trial 2 (3) 0 (0) 6 (5) 9 (5) 2 (5) 19 (4) 0.75
Patient’s refusal 27 (36) 0 (0) 3 (2) 5 (3) 6 (14) 41 (9) 50.001
n=number of patients
Table 3 Treatment of non-entered patients
Institute
A B C D E Total
Therapy n (%) n (%) n (%) n (%) n (%) n (%)
All non-entered
LE 55 (28) 1 (5) 46 (30) 53 (28) 21 (29) 176 (28)
LE+RT 16 (8) 5 (25) 9 (6) 63 (33) 1 (1) 94 (15)
Mastectomy 122 (63) 14 (70) 99 (64) 76 (40) 51 (70) 362 (57)
Eligible non-entered
LE 32 (71) 25 (81) 24 (37) 12 (79) 93 (60)
LE+RT 7 (16) 5 (16) 17 (27) 0 (0) 29 (19)
Mastectomy 6 (13) 1 (3) 23 (36) 3 (21) 33 (21)
Ineligible
LE 23 (16) 1 (5) 21 (25) 29 (23) 9 (15) 83 (17)
LE+RT 9 (6) 5 (25) 4 (3) 46 (36) 1 (2) 65 (14)
Mastectomy 116 (78) 14 (70) 98 (80) 53 (41) 48 (83) 329 (69)
n=number of patients. LE=local excision, LE+RT=local excision+radiotherapy
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compared to those randomised for LE+RT (83 vs 98%,
s.e.=6.9, P=0.031). The patients treated with LE alone had equal
4-years local recurrence-free intervals in and outside the trial
(89%).
DISCUSSION
The results of randomised clinical trials (RCTs) usually serve as the
basis of treatment decisions, even though only a minority of the
patient population will actually participate in trials (Fisher,
1991). Ellenberg (1994) has described a selection process of
patients entered into RCTs together with the generalisation of
results from randomised patients. From the population of patients
with a disorder, only a subgroup may have the type of disease
which is appropriate for the treatment under investigation. Of
these, only part will be screened, only a proportion will be eligible
for randomisation and some will not wish to enter the trial. The
applicability of the trial results is highly dependent on the selection
that occurs in each step.
Entry rates of patients for RCTs and the reasons for non-entry
have been studied by a number of groups (McCusker et al, 1982;
Lee and Breaux, 1983; Martin et al, 1984; Anonymous, 1986; Jack
et al, 1990; Fentiman et al, 1991; Gorst and Johnson, 1992; Kotwall
et al, 1992; Kober and Torp-Pedersen, 1995; Partonen et al, 1996;
Licht et al, 1997) but the effect of selection on the applicability of
the trial results has been investigated in only a few, mainly phar-
maceutical studies (Anonymous, 1986; Gorst and Johnson, 1992;
Kober and Torp-Pedersen, 1995; Licht et al, 1997). To our know-
ledge, the effect of patient selection on applicability of results in
surgical/radiotherapy trials has never been fully analysed. The
present study showed that 52% of all patients with DCIS were
not entered because they did not fulﬁl the eligibility criteria. The
main reason for ineligibility was the extent of the DCIS, the most
important criterion of suitability for BCT. Although 63% of the
lesions was detected by mammography only, a considerable
number (25%) of these lesions were still too large for BCT. As
would be expected, a greater proportion (40%) of the clinically
detected lesions was too large to be treated with BCT.
The variation between the institutes in the proportion of lesions
treated with mastectomy may be caused by the differences in
number of screen detected lesions. Also, institute D treated a
number of cases with involved margins with BCT outside the trial,
which may account for the lower proportion of lesions considered
too large for BCT in this institute.
Other major reasons for ineligibility were a previous (breast)
malignancy and the age of the patient. These eligibility criteria
are necessary to ascertain complete follow-up of all patients, and
to prevent the study from being contaminated by events unrelated
to the DCIS. The non-entry of these patients is unlikely to have a
major inﬂuence on the applicability of the trial results. The varia-
tion between the institutes in the number of patients ineligible due
to a previous contralateral breast cancer may be caused by differ-
ences in follow-up policies for patients with breast cancer.
Additional criteria for selection were used in 36% of all eligible
patients. Other studies report rates of eligible but non-entered
patients of 25–73% (Lee and Breaux, 1983; Jack et al, 1990;
Kotwall et al, 1992). The ﬁve institutes selected for our study are
all specialised cancer centres and the physicians have put much
effort into randomisation of suitable cases with only a few patients
not being considered for entry. Hospitals with active oncology
units have a higher accrual rate in cancer RCTs than other
community hospitals (McCusker et al, 1982). This may account
for the lower proportion of eligible but non-entered patients
compared with other studies. Three factors known to inﬂuence
the entry of eligible patients in RCTs are problems with informed
consent, and doctors’ and patient’s preference for one of the treat-
ment arms in certain subgroups of the eligible patients (Taylor et
al, 1984; Anonymous, 1986; Jack et al, 1990; Gorst and Johnson,
1992; Kober and Torp-Pedersen, 1995; Partonen et al, 1996; Licht
et al, 1997) The reported rates of patient refusal vary from less than
10% to almost half of the eligible patients (McCusker et al, 1982;
Lee and Breaux, 1983; Martin et al, 1984; Jack et al, 1990; Kotwall
et al, 1992). This variation is highly dependent on the type and
stage of the disease, type of treatment, the patients’ occupational
level and the physicians’ skills of informing the patient about the
trial (McCusker et al, 1982). In our study, large differences were
seen in refusal rates between the various institutes, possibly reﬂect-
ing differences in consent procedure. Williams and Zwitter (1994)
reported large differences in informed consent used between Medi-
terranean and non-Mediterranean participating clinicians in
European multicentre randomised clinical trials, with the latter
being more likely to carry out full consent procedures than those
from Mediterranean countries.
Personal perceptions on ‘optimal treatment policies’ may result
in physicians’ reluctance to randomise certain subgroups of
patients for one of the treatment arms (Taylor et al, 1984). Our
study shows that in four of the ﬁve institutes clinicians did not
enter eligible patients based on the histologic subtype of DCIS.
Results of non-randomised studies based on (morphologic) classi-
ﬁcation of DCIS (Page et al, 1982; Lagios et al, 1989; Silverstein et
al, 1990; Bellamy et al, 1993; Eusebi et al, 1994) have inﬂuenced
the participating clinicians’ opinions on the treatment of subtypes
of the disease. Of all randomised patients the histology was
reviewed. The preference of institute D to treat comedo-type DCIS
with mastectomy or radiotherapy outside the trial resulted in the
observation that of all randomised patients from institute D 78%
had well differentiated DCIS (according to a classiﬁcation based
on cytonuclear factors (Holland et al, 1994)); in other institutes
the rate of the three subtypes is more equally distributed. Conse-
quently, the randomised patients may not be representative for
all eligible patients with respect to differentiation type. The risk
factor analysis of the EORTC 10853 trial showed that radiotherapy
reduced the risk of recurrence in all histological types of DCIS
(Bijker et al, 2001).
A randomised trial comparing mastectomy with BCT for DCIS has
never been conducted and it is unlikely that this will ever occur.
Nevertheless, from all non-randomised studies there is strong
evidence that mastectomy has signiﬁcantly lower local recurrence
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Table 4 4-year local recurrence-free interval rates of the randomised
patients, of those eligible non-entered, and ineligible patients
Treatment
M LE LE+RT
Number ineligible 329 83 65
Number of events 5 11 6
4 years LR free (%) 98 85 86
Number at risk 147 23 18
Standard error 1.2 6.9 7.5
Number eligible but excluded 33 93 29
Number of events 0 6 4
4 years LR free (%) 100 93 74
Number at risk 14 28 8
Standard error 0.0 4.7 13.4
Number in EORTC trial 135 133
Number of events 19 12
4 years LR free (%) 89 98
Number at risk 86 91
Standard error 2.9 1.3
M=mastectomy; LE=local excision; LE+RT=local excision+radiotherapy; LR=local
recurrence.
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mal local control, still a substantial number of patients (40%) were
offered a mastectomy, which is a reasonable option as this large series
shows only a 2% chest wall recurrence rate at 4 years. This is consis-
tent with the reported rates, ranging from 1 to 4% (Cataliotti et al,
1992; Silverstein et al, 1995; Warneke et al, 1995).
When the outcome of BCT of non-entered patients is compared
with that of the randomised patients, there seems to be a larger
beneﬁcial effect of RT on local control for those treated in the trial.
Although the short duration of follow-up does not permit us to
draw any deﬁnite conclusions from this ﬁnding, it suggests that
patient selection has caused this effect. Many patients with a
presumed worse prognosis, like those with involved margins, were
treated with LE+RT outside the trial. This may explain why the 4-
year local recurrence rates in the non-entered patients treated with
LE+RT are relatively high compared to the patients in the trial
treated with LE+RT. It might also indicate the importance of a
complete excision, even with the application of RT (Silverstein et
al, 1999; Bijker et al, 2001). In contrast, the non-entered patients
treated with local excision alone had more similar 4-years local
recurrence free rates in comparison to those patients treated with
local excision in the trial, suggesting that LE alone is employed
in those non-entered patients who were considered to have a low
risk for local recurrence.
A few other studies have shown that the outcome of patients
treated within RCTs is better compared to those undergoing the
same treatment outside trials, which is mainly explained by ‘posi-
tive’ selection of patients: patients with a presumed worse
prognosis are more likely to be excluded from participation (Anon-
ymous, 1986; Gorst and Johnson, 1992: Kober and Torp-Pedersen,
1995; Licht et al, 1997). The only cancer RCTs that have shown
this effect are two leukaemia trials; of two other studies that were
found one investigated the effect of selection on outcome of anti-
depressant treatment and one on a pharmaceutical intervention
after acute myocardial infarction.
Two important questions can be addressed related to the gener-
alisability of the results of this trial. (1) For what proportion of
patients with DCIS BCT is a reasonable option with a low risk
of recurrence, and for whom a mastectomy is preferred because
of the extent of the DCIS? (2) Do all patients with DCIS beneﬁt
from RT after local excision for DCIS? We were able to study
patient selection in ﬁve institutes. Our study shows that of all
patients with DCIS, only 70% could be offered BCT. Although trial
participation was considered in almost all eligible patients, only
two thirds were entered, with large differences between the centres
and varying reasons for non-entry. Randomised patients treated
with LE+RT had better 4-year local recurrence-free rates than those
treated with LE+RT outside the trial. This indicates that the quan-
titative results of this trial (i.e. the reduction of the 4-years local
recurrence rate with 38% by the application of RT) might not be
generalisable to all patients with DCIS eligible for BCT. Especially
disconcerting is the observed selection with respect to the differen-
tiation type. Our ﬁndings indicate the importance of prospective
registration and follow-up of non-randomised patients for evaluat-
ing the applicability of the trial results to the general population
with the disease (Ellenberg, 1994; Olschewski and Scheuren,
1985). Before committing an institute to participation, future trials
might further need a quality assessment of the candidate centre
including a review of a possible predetermined position regarding
the treatment to be investigated in the study.
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